Angioletta Lasagna

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 35

Top Topics

Infectious Diseases

Emergency Medicine

Ejection Fraction

Top Venues

Future oncology (London, England)

Pathogens (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Chiara Rossi, Frediano Socrate Inzani, Stefania Cesari, Gianpiero Rizzo, Marco Paulli, Paolo Pedrazzoli, Angioletta Lasagna, Marco Lucioni
The Role of Oncogenic Viruses in the Pathogenesis of Sporadic Breast Cancer: A Comprehensive Review of the Current Literature. Pathogens (Basel, Switzerland) 13 (6) (2024)
Angioletta Lasagna, Paolo Sacchi
The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management. Cancers 16 (4) (2024)
Chiara Rossi, Frediano Socrate Inzani, Stefania Cesari, Gianpiero Rizzo, Marco Paulli, Paolo Pedrazzoli, Angioletta Lasagna, Marco Lucioni
The Role of Oncogenic Viruses in the Pathogenesis of Sporadic Breast Cancer: A Comprehensive Review of the Current Literature. Pathogens (Basel, Switzerland) 13 (6) (2024)
Chiara Rossi, Frediano Socrate Inzani, Stefania Cesari, Gianpiero Rizzo, Marco Paulli, Paolo Pedrazzoli, Angioletta Lasagna, Marco Lucioni
The Role of Oncogenic Viruses in the Pathogenesis of Sporadic Breast Cancer: A Comprehensive Review of the Current Literature. Pathogens (Basel, Switzerland) 13 (6) (2024)
Angioletta Lasagna, Paolo Sacchi
The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management. Cancers 16 (4) (2024)
Angioletta Lasagna, Federica Mascaro, Simone Figini, Sara Basile, Giulia Gambini, Catherine Klersy, Marco Vincenzo Lenti, Antonio Di Sabatino, Alice Di Benedetto, Monica Calvi, Raffaele Bruno, Paolo Sacchi, Paolo Pedrazzoli
Impact of proton pump inhibitors on the onset of gastrointestinal immune-related adverse events during immunotherapy. Cancer medicine (2023)
Angioletta Lasagna, Irene Cassaniti, Francesca Arena, Federica Bergami, Elena Percivalle, Giuditta Comolli, Antonella Sarasini, Alessandro Ferrari, Daniela Cicognini, Roberta Schiavo, Giuliana Lo Cascio, Paolo Pedrazzoli, Fausto Baldanti
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up. International journal of molecular sciences 24 (7) (2023)
Angioletta Lasagna, Paolo Pedrazzoli, Raffaele Bruno, Paolo Sacchi
Postvaccination immune-mediated hepatitis: what do we really know? Immunotherapy 15 (9) (2023)
Angioletta Lasagna, Giuseppe Albi, Simone Figini, Sara Basile, Paolo Sacchi, Raffaele Bruno, Paolo Pedrazzoli
Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience. Cancers 15 (4) (2023)
Angioletta Lasagna, Paolo Pedrazzoli, Raffaele Bruno, Paolo Sacchi
Postvaccination immune-mediated hepatitis: what do we really know? Immunotherapy (2023)
Angioletta Lasagna, Paolo Pedrazzoli, Raffaele Bruno, Paolo Sacchi
Postvaccination immune-mediated hepatitis: what do we really know? Immunotherapy 15 (9) (2023)
Angioletta Lasagna, Antonella Brunello, Nicola Silvestris, Paolo Pedrazzoli, Massimo Di Maio, Saverio Cinieri
Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology. Tumori (2023)
Angioletta Lasagna, Paolo Pedrazzoli, Raffaele Bruno, Paolo Sacchi
Postvaccination immune-mediated hepatitis: what do we really know? Immunotherapy (2023)
Angioletta Lasagna, Giuseppe Albi, Simone Figini, Sara Basile, Paolo Sacchi, Raffaele Bruno, Paolo Pedrazzoli
Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience. Cancers 15 (4) (2023)
Angioletta Lasagna, Giuseppe Albi, Simone Figini, Sara Basile, Paolo Sacchi, Raffaele Bruno, Paolo Pedrazzoli
Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience. Cancers 15 (4) (2023)
Angioletta Lasagna, Paolo Pedrazzoli, Raffaele Bruno, Paolo Sacchi
Postvaccination immune-mediated hepatitis: what do we really know? Immunotherapy (2023)
Angioletta Lasagna, Paolo Pedrazzoli, Raffaele Bruno, Paolo Sacchi
Postvaccination immune-mediated hepatitis: what do we really know? Immunotherapy 15 (9) (2023)
Angioletta Lasagna, Irene Cassaniti, Paolo Sacchi, Simone Figini, Fausto Baldanti, Raffaele Bruno, Paolo Pedrazzoli
The 'hit-and-run' strategy and viral carcinogenesis. Future oncology (London, England) (2023)
Angioletta Lasagna, Bryan Arlunno, Ilaria Imarisio
A case report of pulmonary nocardiosis during pembrolizumab: the emerging challenge of the infections on immunotherapy. Immunotherapy (2022)
Francesco Serra, Irene Cassaniti, Daniele Lilleri, Paolo Pedrazzoli, Fausto Baldanti, Angioletta Lasagna
Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors. Immunotherapy 14 (6) (2022)
Angioletta Lasagna, Mara De Amici, Chiara Rossi, Valentina Zuccaro, Marta Corbella, Greta Petazzoni, Francesco Comandatore, Lucia Sacchi, Giorgia Testa, Elisa Ferraris, Gianpiero Rizzo, Richard Tancredi, Alessandra Ferrari, Marco Lucioni, Paolo Sacchi, Raffaele Bruno, Paolo Pedrazzoli
The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study. Pathogens (Basel, Switzerland) 11 (12) (2022)
Angioletta Lasagna, Mara De Amici, Chiara Rossi, Valentina Zuccaro, Marta Corbella, Greta Petazzoni, Francesco Comandatore, Lucia Sacchi, Giorgia Testa, Elisa Ferraris, Gianpiero Rizzo, Richard Tancredi, Alessandra Ferrari, Marco Lucioni, Paolo Sacchi, Raffaele Bruno, Paolo Pedrazzoli
The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study. Pathogens (Basel, Switzerland) 11 (12) (2022)
Angioletta Lasagna, Mara De Amici, Chiara Rossi, Valentina Zuccaro, Marta Corbella, Greta Petazzoni, Francesco Comandatore, Lucia Sacchi, Giorgia Testa, Elisa Ferraris, Gianpiero Rizzo, Richard Tancredi, Alessandra Ferrari, Marco Lucioni, Paolo Sacchi, Raffaele Bruno, Paolo Pedrazzoli
The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study. Pathogens (Basel, Switzerland) 11 (12) (2022)
Angioletta Lasagna, Matteo Ghiara, Antonio A Mahagna, Ambrogio A Lombardini, Fabrizio Cuzzocrea, Camillo Porta
Skeletal muscle metastases: pitfalls and challenges of a highly inhospitable environment. Future oncology (London, England) 18 (8) (2022)
Angioletta Lasagna, Marco Vincenzo Lenti, Irene Cassaniti, Paolo Sacchi
Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report. Immunotherapy 14 (12) (2022)
Angioletta Lasagna, Mara De Amici, Chiara Rossi, Valentina Zuccaro, Marta Corbella, Greta Petazzoni, Francesco Comandatore, Lucia Sacchi, Giorgia Testa, Elisa Ferraris, Gianpiero Rizzo, Richard Tancredi, Alessandra Ferrari, Marco Lucioni, Paolo Sacchi, Raffaele Bruno, Paolo Pedrazzoli
The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study. Pathogens (Basel, Switzerland) 11 (12) (2022)
Angioletta Lasagna, Irene Cassaniti, Paolo Sacchi, Fausto Baldanti, Raffaele Bruno, Paolo Pedrazzoli
Infectious complications and immunotherapy: old pitfalls and new horizons. Future oncology (London, England) 18 (22) (2022)
Angioletta Lasagna, Valentina Zuccaro, Paolo Sacchi, Silvia Chiellino, Raffaele Bruno, Paolo Pedrazzoli
Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? Future oncology (London, England) 17 (13) (2021)
Angioletta Lasagna, Fabrizio Cuzzocrea, Gaia Maccario, Antonio Mahagna, Paolo Sacchi, Mario U Mondelli
Bone metastases and hepatocellular carcinoma: some food for thought. Future oncology (London, England) 17 (29) (2021)
Serena Di Cosimo, Barbara Tagliaferri, Daniele Generali, Fabiola Giudici, Francesco Agustoni, Antonio Bernardo, Karen Borgonovo, Gabriella Farina, Giovanna Luchena, Andrea Luciani, Franco Nolè, Laura Palmeri, Filippo Pietrantonio, Guido Poggi, Paolo Andrea Zucali, Emanuela Balletti, Giovanna Catania, Ottavia Bernocchi, Federica D'Antonio, Monica Giordano, Francesco Grossi, Angioletta Lasagna, Nicla La Verde, Mariangela Manzoni, Benedetta Montagna, Angelo Olgiati, Alessandra Raimondi, Irene Rampinelli, Elena Verri, Alberto Zaniboni, Massimo Di Maio, Giordano Beretta, Marco Danova
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. Cancers 13 (6) (2021)
Angioletta Lasagna, Elisa Ferraris, Alessandra Greco, Richard J Tancredi, Paolo Pedrazzoli
Reply to Y. Ergun et al. JCO oncology practice 17 (7) (2021)
Angioletta Lasagna, Marta Muzzana, Paolo Pedrazzoli
Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research. Immunotherapy 13 (17) (2021)
Marta Muzzana, Paolo Pedrazzoli, Angioletta Lasagna
G-CSF and G-CSF-related vasculitis: a systematic review of the literature and intriguing future research perspectives. Future oncology (London, England) 17 (33) (2021)
Angioletta Lasagna, Valentina Zuccaro, Elisa Ferraris, Marta Corbella, Raffaele Bruno, Paolo Pedrazzoli
COVID-19 and breast cancer: may the microbiome be the issue? Future oncology (London, England) 17 (2) (2020)
Angioletta Lasagna, Teresa Monaco, Ilaria Imarisio, Silvia Brugnatelli
In reply to: "A COVID-19 screening tool for oncology telephone triage". Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 29 (2) (2020)